BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 31079797)

  • 1. Oncolytic Immunotherapy.
    Hennessy ML; Bommareddy PK; Boland G; Kaufman HL
    Surg Oncol Clin N Am; 2019 Jul; 28(3):419-430. PubMed ID: 31079797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
    Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
    Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating oncolytic viruses in combination cancer immunotherapy.
    Bommareddy PK; Shettigar M; Kaufman HL
    Nat Rev Immunol; 2018 Aug; 18(8):498-513. PubMed ID: 29743717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic Immunotherapy for Treatment of Cancer.
    Tsun A; Miao XN; Wang CM; Yu DC
    Adv Exp Med Biol; 2016; 909():241-83. PubMed ID: 27240460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of oncolytic virus immunotherapies to subvert cancer immune evasion.
    Workenhe ST; Verschoor ML; Mossman KL
    Future Oncol; 2015; 11(4):675-89. PubMed ID: 25686121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for thoracic oncology gone viral.
    Patel MR
    Immunotherapy; 2018 Apr; 10(5):383-390. PubMed ID: 29473469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving Status of Clinical Immunotherapy with Oncolytic Adenovirus.
    Farrera-Sal M; Moya-Borrego L; Bazan-Peregrino M; Alemany R
    Clin Cancer Res; 2021 Jun; 27(11):2979-2988. PubMed ID: 33526422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic virus therapy: A new era of cancer treatment at dawn.
    Fukuhara H; Ino Y; Todo T
    Cancer Sci; 2016 Oct; 107(10):1373-1379. PubMed ID: 27486853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies.
    Workenhe ST; Mossman KL
    Mol Ther; 2014 Feb; 22(2):251-256. PubMed ID: 24048442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of oncolytic virotherapy: from genetic modification to combination therapy.
    Lan Q; Xia S; Wang Q; Xu W; Huang H; Jiang S; Lu L
    Front Med; 2020 Apr; 14(2):160-184. PubMed ID: 32146606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans.
    Cerullo V; Koski A; Vähä-Koskela M; Hemminki A
    Adv Cancer Res; 2012; 115():265-318. PubMed ID: 23021247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virus specific tolerance enhanced efficacy of cancer immuno-virotherapy.
    Sobhanimonfared F; Bamdad T; Sadigh ZA; Choobin H
    Microb Pathog; 2020 Mar; 140():103957. PubMed ID: 31891795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies.
    van Vloten JP; Workenhe ST; Wootton SK; Mossman KL; Bridle BW
    J Immunol; 2018 Jan; 200(2):450-458. PubMed ID: 29311387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SnapShot: Cancer Immunotherapy with Oncolytic Viruses.
    Gujar S; Bell J; Diallo JS
    Cell; 2019 Feb; 176(5):1240-1240.e1. PubMed ID: 30794777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Circuits of Immune Sensing and Response to Oncolytic Virotherapy.
    Bhatt DK; Daemen T
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic HSV as a vector in cancer immunotherapy.
    Li H; Zhang X
    Methods Mol Biol; 2010; 651():279-90. PubMed ID: 20686972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining oncolytic virotherapy and tumour vaccination.
    Bridle BW; Hanson S; Lichty BD
    Cytokine Growth Factor Rev; 2010; 21(2-3):143-8. PubMed ID: 20226716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulation in Oncolytic Measles Virotherapy.
    Dietz L; Engeland CE
    Methods Mol Biol; 2020; 2058():111-126. PubMed ID: 31486034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy.
    Niemann J; Woller N; Brooks J; Fleischmann-Mundt B; Martin NT; Kloos A; Knocke S; Ernst AM; Manns MP; Kubicka S; Wirth TC; Gerardy-Schahn R; Kühnel F
    Nat Commun; 2019 Jul; 10(1):3236. PubMed ID: 31324774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular insights and promise of oncolytic virus based immunotherapy.
    Iyer M; Ravichandran N; Karuppusamy PA; Gnanarajan R; Yadav MK; Narayanasamy A; Vellingiri B
    Adv Protein Chem Struct Biol; 2024; 140():419-492. PubMed ID: 38762277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.